Clinical trials: Dizziness and Vertigo
Dizziness, Nausea
Efficacy of a Non-invasive Vestibular System Masking for Improving Outcomes Following Acute Unilateral Vestibulopathy
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population.
- Trial name
- NCT04226976
- Testing
- Otoband
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Otolith Labs
Postoperative Pain
Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients
This is a randomized, double-blind, multicenter, repeat-dose study of fixed doses of Q8003 12 mg/8 mg given q6hr compared to morphine sulfate 24 mg and oxycodone hydrochloride 16 mg given q6hr for the management of acute moderate…
- Trial name
- NCT01280331
- Testing
- Q8003 (morphine sulfate and oxycodone hydrochloride), Morphine sulfate, Oxycodone HCl
- Where
- 4 sites in United States
- Volunteers
- 375 people
- Sponsor
- QRxPharma Inc.
Symptomatic Neurogenic Orthostatic Hypotension
Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, multi-center, open-label study to evaluate the safety and tolerability of ampreloxetine in subjects with primary autonomic failures (MSA, PD, and PAF) and symptomatic nOH over 182 weeks.
- Trial name
- OAK (NCT04095793)
- Testing
- ampreloxetine
- Where
- 55 sites in United States, Australia and 16 more
- Volunteers
- 110 people
- Sponsor
- Theravance Biopharma
Brain Concussion, Vestibular Disorder
Portable Mixed Reality-based Platform for Assessment of Progress in Multisensory Rehabilitation Strategies Post-TBI
The goal of this comparative pilot study is to provide evidence that Praxis, a portable testbed with low-cost wearable sensors and a mixed reality environment, can deliver effective multisensory rehabilitation exercises with…
- Conditions
- Brain Concussion, Vestibular Disorder, Cognition Disorder, Mild Traumatic Brain Injury
- Trial name
- Praxis (NCT06314464)
- Testing
- Praxis, Supervised cardiovascular exercise
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- BlueHalo
Arrhythmias, Cardiac, Palpitation
Ambulatory Leadless Electrocardiogram Recorder Trial Feasibility
The goal of this study is to compare the heart signals that are received by a new heart monitoring device called the HeartWatch to heart signals that are recorded by existing monitors used in cardiology clinics today.
- Conditions
- Arrhythmias, Cardiac, Palpitation, Syncope, Light Headedness
- Trial name
- ALERT (NCT05821465)
- Testing
- HeartWatch
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- HelpWear Inc.
Lymphoma
Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)
To understand the safety and efficacy of Revlimid® Capsules 2.5 mg and 5 mg (hereinafter referred to as Revlimid) under actual conditions of use in patients with relapsed or refractory adult T-cell leukemia lymphoma (hereinafter…
- Trial name
- NCT03098589
- Testing
- Revlimid
- Where
- Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Meniere's Disease
SPI-1005 for the Treatment of Patients With Meniere's Disease
This study will evaluate the safety, efficacy, and Pharmacokinetics (PK) of two dose levels of SPI-1005 administered for 28 days compared to placebo in patients with Meniere's disease.
- Trial name
- NCT03325790
- Testing
- 200mg SPI-1005 BID, 400mg SPI-1005 BID
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Vestibular Vertigo
AM-125 in the Treatment of Acute Peripheral Vertigo Following Neurosurgery
Treatment of vertigo after removal of a tumor of the balance and hearing nerve after neurosurgery, which damages or cuts the vestibular nerve (balance).
- Trial name
- TRAVERS (NCT03908567)
- Testing
- Intranasal Drug, Oral Tablet
- Where
- France
- Volunteers
- 124 people
- Sponsor
- Auris Medical AG
Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- AVERTS-2 (NCT02717442)
- Testing
- OTO-104
- Where
- United States
- Volunteers
- 176 people
- Sponsor
- Otonomy, Inc.
Vertigo
A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation
The purpose of this study is to determine the efficacy and safety of Betahistine Mesilate in the treatment of patients with vertigo caused by Cerebral Infarction in posterior circulation.
- Trial name
- NCT00474409
- Testing
- Merislon
- Where
- 4 sites in China
- Sponsor
- Eisai Inc.
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Dizziness, Vertigo
Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness
Vestibular disorders are among the most common causes of disability in society and affect over 50% of the population over the age of 65 and a significant percentage of the younger population.
- Conditions
- Dizziness, Vertigo, Vestibular Migraine, Vestibular Neuritis
- Trial name
- NCT05157399
- Testing
- Otoband
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Otolith Labs
Ototoxicity
SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity
The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing…
- Trial name
- NCT02819856
- Testing
- SPI-1005 Ebselen 200mg Capsule x1, SPI-1005 Ebselen 200mg Capsule x2, SPI-1005 Ebselen 200mg Capsule x3
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Vertigo
A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo
A Multicenter, Double-Blind, Placebo Controlled, Phase Ⅱa clinical trial to enroll 120 patients with Vertigo Caused By Posterior Circulation Infarction during 7 days, then to evaluate the efficacy of different dose of…
- Trial name
- NCT02299804
- Testing
- Levophencynonate Hydrochloric
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Sihuan Pharmaceutical Holdings Group Ltd.
Vertigo, Peripheral
Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin
Evaluation of the non inferiority of Meclin (meclizine) versus Dramin (Dimenhydrinate) to treat the symptoms of acute vertigo from peripheral origin after up to 4 weeks of treatment; Evaluation of impact on quality of life in…
- Trial name
- NCT02112578
- Testing
- Meclizine, Dimenhydrinate
- Where
- 7 sites in Brazil
- Volunteers
- 292 people
- Sponsor
- Apsen Farmaceutica S.A.
Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure
Positive Care Effect of the Digital Health Assistant ADELE Blood Pressure for Hypertension Patients
High blood pressure (hypertension) can cause damage to vital organs such as the heart, kidneys, eyes, brain and blood vessels. The risk of developing high blood pressure increases with age.
- Conditions
- Essential (Primary) Hypertension, Hypertensive Heart Disease With (Congestive) Heart Failure, Hypertensive Heart Disease Without (Congestive) Heart Failure, Other Secondary Hypertension
- Trial name
- A0007 (NCT06663280)
- Testing
- Digital health assistant ADELE
- Where
- 2 sites in Germany
- Volunteers
- 108 people
- Sponsor
- Alma Phil Gmbh
Vestibular Function Tests, Dizziness
Efficacy of a Transcranial Vibrating System for Minimizing Dizziness During Caloric Testing
Vestibular disorders are among the most common causes of disability in society. Vestibular dysfunction affects over one third of the population over the age of 40 and a significant percentage of the younger population.
- Trial name
- NCT03618199
- Testing
- Efficacy of transcranial vibrating system on mitigating dizziness and nausea during caloric testing
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Otolith Labs
Positional Vertigo, Vertigo
Visual Feedback Goggle for Positional Vertigo Treatment
Benign Paroxysmal Positional Vertigo (BPPV) is one of the most common causes of vertigo and the most common vestibular disorder of the inner ear.
- Trial name
- NCT00729885
- Testing
- Goggle with 20 degree error, Optimized Goggle
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Vertigone Inc.
Symptomatic Neurogenic Orthostatic Hypotension, MSA
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension, MSA, Parkinson's Disease (PD), Pure Autonomic Failure (PAF)
- Trial name
- REDWOOD (NCT03829657)
- Testing
- ampreloxetine
- Where
- 82 sites in United States, Australia and 17 more
- Volunteers
- 203 people
- Sponsor
- Theravance Biopharma
Meniere Disease
Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease
The purpose of this study is to evaluate the effectiveness of OTO-104 for the treatment of Meniere's disease.
- Trial name
- NCT03664674
- Testing
- OTO-104
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 148 people
- Sponsor
- Otonomy, Inc.